Antihemophilic Factor (Recombinant) (Kovaltry and Novoeight) and Daclizumab Subcutaneous
Determining the interaction of Antihemophilic Factor (Recombinant) (Kovaltry and Novoeight) and Daclizumab Subcutaneous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: antihemophilic factor
Brand name: Hemofil-M, Koate-DVI, Monoclate-P, Advate, Adynovate, Afstyla, Eloctate with Fc Fusion Protein, Helixate FS, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha, Jivi, Obizur
Synonyms: Antihemophilic factor (human), Antihemophilic Factor (Human)
Generic Name: daclizumab
Brand name: Zinbryta, Zenapax
Synonyms: Daclizumab
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Antihemophilic Factor (Recombinant) (Kovaltry and Novoeight)-Dacogen
- Antihemophilic Factor (Recombinant) (Kovaltry and Novoeight)-Dacomitinib
- Antihemophilic Factor (Recombinant) (Kovaltry and Novoeight)-Dactinomycin
- Antihemophilic Factor (Recombinant) (Kovaltry and Novoeight)-Dactinomycin Injection
- Antihemophilic Factor (Recombinant) (Kovaltry and Novoeight)-Dactinomycin Intravenous
- Antihemophilic Factor (Recombinant) (Kovaltry and Novoeight)-Daklinza
- Daclizumab Subcutaneous-Antihemophilic Factor (Recombinant) (Nuwiq)
- Daclizumab Subcutaneous-Antihemophilic Factor (Recombinant) (Recombinate)
- Daclizumab Subcutaneous-Antihemophilic Factor (Recombinant) (Xyntha)
- Daclizumab Subcutaneous-Antihemophilic factor (recombinant) pegylated-aucl Intravenous
- Daclizumab Subcutaneous-Antihemophilic factor (recombinant) porcine sequence Intravenous
- Daclizumab Subcutaneous-Antihemophilic factor human